Clinical trials: Imipenem
Pneumonia
Evaluation of Innovative Tools in Development of Antibiotics
The investigators will determine the difference of pharmacokinetics of ciprofloxacin and imipenem between healthy volunteers and intensive care patients suffering from pneumonia in plasma and at the target site - lung - using…
- Trial name
- NCT03177720
- Testing
- Ciprofloxacin, Imipenem
- Where
- Austria
- Volunteers
- 10 people, healthy volunteers welcome
- Sponsor
- Medical University of Vienna
Bacterial Infections
Study to Evaluate Safety, Tolerability, and Pharmacokinetics of XNW4107 Alone or in Combination With Imipenem/Cilastatin
This is a 3-part, first-in-human study to evaluate the safety, tolerability and pharmacokinetics of escalating doses of XNW4107 given as intravenous (IV) infusion in healthy male subjects.
- Trial name
- NCT04482569
- Testing
- XNW4107
- Where
- United States
- Volunteers
- 88 people, healthy volunteers welcome
- Sponsor
- Evopoint Biosciences Inc.
Bacterial Infections
Pharmacokinetics of XNW4107 in Subjects With Various Degrees of Renal Function
This is a Phase 1, open-label study to assess the PK, safety and tolerability of XNW4107, imipenem and cilastatin administered by 60-minute (60-min) IV infusion to adults with various degrees of renal insufficiency as compared to…
- Trial name
- NCT04787562
- Testing
- XNW4107, Imipenem/Cilastatin
- Where
- 2 sites in United States
- Volunteers
- 39 people, healthy volunteers welcome
- Sponsor
- Evopoint Biosciences Inc.
Bacterial Infections
Intrapulmonary Pharmacokinetics of XNW4107, Imipenem and Cilastatin in Healthy Subjects
This is a Phase 1, open-label, single-center study of XNW4107 and imipenem/cilastatin administered intravenously.
- Trial name
- NCT04802863
- Testing
- XNW4107, Imipenem/Cilastatin
- Where
- United States
- Volunteers
- 21 people, healthy volunteers welcome
- Sponsor
- Evopoint Biosciences Inc.